pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Sep 25·1 min read
save

Medra, 2026 Endpoints 11 winner, aims to build self-driving labs

Sep 25, 2026·read at Endpoints ↗Positive

Medra, the recent winner of the Endpoints 11 2026 competition, announced plans to develop autonomous laboratory systems.

The company's founder, who just completed a PhD in robotics, said the goal is to create self-driving labs that can run experiments without human intervention.

The award highlights Medra’s innovative approach, and the initiative could accelerate drug discovery by increasing efficiency and reducing manual labor.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Endpoints 11 2026 winner Medra wants to create self-driving labs”

read at Endpoints ↗
83 words · retrieved Sep 25
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 14h agoAnthropic’s one-person biotech buy; Jake Van Naarden’s dealmaking strategy; and moreEndpoints
  • 1d agoSanofi may seek higher European drug prices, not withhold launches, under Trump dealEndpoints
  • 1d agoGilead CAR-T on partial clinical hold; Agios' PDUFA date pushed backEndpoints
  • 1d agoAstraZeneca says reorg could mean R&D cuts and trials shifted to emerging marketsEndpoints
  • 1d agoAnthropic's Nathan Frey on biopharma partners, M&A and pipelineEndpoints